Literature DB >> 22671690

Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders.

Daryl L Davies1, Marco Bortolato, Deborah A Finn, Marcia J Ramaker, Segev Barak, Dorit Ron, Jing Liang, Richard W Olsen.   

Abstract

Alcohol abuse and dependence have a staggering socioeconomic impact, yet current therapeutic strategies are largely inadequate to treat these disorders. Thus, the development of new strategies that can effectively prevent alcohol use disorders (AUDs) is of paramount importance. Currently approved medications attempt to deter alcohol intake by blocking ethanol metabolism or by targeting the neurochemical systems downstream of the cascades leading to craving and dependence. Unfortunately, these medications have provided only limited success as indicated by the continued high rates of alcohol abuse and alcoholism. The lack of currently available effective treatment strategies is highlighted by the urgent call by the NIAAA to find new and paradigm-changing therapeutics to either prevent or treat alcohol-related problems. This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs.
Copyright © 2012 by the Research Society on Alcoholism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22671690      PMCID: PMC3443504          DOI: 10.1111/j.1530-0277.2012.01846.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  68 in total

1.  Long-term reduction in ventral tegmental area dopamine neuron population activity following repeated stimulant or ethanol treatment.

Authors:  Roh-Yu Shen; Kar-Chan Choong; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2006-05-12       Impact factor: 13.382

2.  Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration.

Authors:  Thomas Cremers; Bjarke Ebert
Journal:  Eur J Pharmacol       Date:  2007-01-19       Impact factor: 4.432

3.  Dihydromyricetin as a novel anti-alcohol intoxication medication.

Authors:  Yi Shen; A Kerstin Lindemeyer; Claudia Gonzalez; Xuesi M Shao; Igor Spigelman; Richard W Olsen; Jing Liang
Journal:  J Neurosci       Date:  2012-01-04       Impact factor: 6.167

4.  Allopregnanolone influences the consummatory processes that govern ethanol drinking in C57BL/6J mice.

Authors:  Matthew M Ford; Gregory P Mark; Jeffrey D Nickel; Tamara J Phillips; Deborah A Finn
Journal:  Behav Brain Res       Date:  2007-02-23       Impact factor: 3.332

5.  Ivermectin reduces alcohol intake and preference in mice.

Authors:  Megan M Yardley; Letisha Wyatt; Sheraz Khoja; Liana Asatryan; Marcia J Ramaker; Deborah A Finn; Ronald L Alkana; Nhat Huynh; Stan G Louie; Nicos A Petasis; Marco Bortolato; Daryl L Davies
Journal:  Neuropharmacology       Date:  2012-03-23       Impact factor: 5.250

6.  Topiramate for treating alcohol dependence: a randomized controlled trial.

Authors:  Bankole A Johnson; Norman Rosenthal; Julie A Capece; Frank Wiegand; Lian Mao; Karen Beyers; Amy McKay; Nassima Ait-Daoud; Raymond F Anton; Domenic A Ciraulo; Henry R Kranzler; Karl Mann; Stephanie S O'Malley; Robert M Swift
Journal:  JAMA       Date:  2007-10-10       Impact factor: 56.272

7.  Functional gene expression differences between inbred alcohol-preferring and -non-preferring rats in five brain regions.

Authors:  Mark W Kimpel; Wendy N Strother; Jeanette N McClintick; Lucinda G Carr; Tiebing Liang; Howard J Edenberg; William J McBride
Journal:  Alcohol       Date:  2007-03       Impact factor: 2.405

8.  GABAergic modulation of binge-like ethanol intake in C57BL/6J mice.

Authors:  Eileen M Moore; Kristen M Serio; Karen J Goldfarb; Sandra Stepanovska; David N Linsenbardt; Stephen L Boehm
Journal:  Pharmacol Biochem Behav       Date:  2007-07-25       Impact factor: 3.533

9.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.

Authors:  Pia Steensland; Jeffrey A Simms; Joan Holgate; Jemma K Richards; Selena E Bartlett
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

10.  Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption.

Authors:  S Barak; S Ahmadiantehrani; V Kharazia; D Ron
Journal:  Transl Psychiatry       Date:  2011       Impact factor: 6.222

View more
  10 in total

1.  The importance of animals in advancing research on alcohol use disorders.

Authors:  Christa M Helms; Richard L Bell; Allyson J Bennett; Daryl L Davies; Julia A Chester; Therese A Kosten; Robert F Leeman; Sangeeta Panicker; Donna M Platt; Jeff L Weiner; Scott Edwards
Journal:  Alcohol Clin Exp Res       Date:  2015-04       Impact factor: 3.455

Review 2.  Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.

Authors:  Jing Liang; Richard W Olsen
Journal:  Acta Pharmacol Sin       Date:  2014-08       Impact factor: 6.150

Review 3.  [Nalmefene: a novel pharmacotherapeutic option for alcoholism].

Authors:  M Soyka
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

4.  Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.

Authors:  Verica Milivojevic; Gustavo A Angarita; Gretchen Hermes; Rajita Sinha; Helen C Fox
Journal:  Alcohol Clin Exp Res       Date:  2020-06-12       Impact factor: 3.455

Review 5.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

6.  Involvement of Purinergic P2X4 Receptors in Alcohol Intake of High-Alcohol-Drinking (HAD) Rats.

Authors:  Kelle M Franklin; Sheketha R Hauser; Amy W Lasek; Richard L Bell; William J McBride
Journal:  Alcohol Clin Exp Res       Date:  2015-09-03       Impact factor: 3.455

7.  Activation of extrasynaptic δ-GABAA receptors globally or within the posterior-VTA has estrous-dependent effects on consumption of alcohol and estrous-independent effects on locomotion.

Authors:  Laverne C Melón; Zachary T Nolan; Delphine Colar; Eileen M Moore; Stephen L Boehm
Journal:  Horm Behav       Date:  2017-09-20       Impact factor: 3.587

Review 8.  Nicotinic receptor modulation to treat alcohol and drug dependence.

Authors:  Shafiqur Rahman; Eric A Engleman; Richard L Bell
Journal:  Front Neurosci       Date:  2015-01-15       Impact factor: 4.677

9.  JNK pathway activation is controlled by Tao/TAOK3 to modulate ethanol sensitivity.

Authors:  David Kapfhamer; Ian King; Mimi E Zou; Jana P Lim; Ulrike Heberlein; Fred W Wolf
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

Review 10.  P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders.

Authors:  Kelle M Franklin; Liana Asatryan; Michael W Jakowec; James R Trudell; Richard L Bell; Daryl L Davies
Journal:  Front Neurosci       Date:  2014-06-24       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.